Kendra J. Bjoraker

Kendra J. Bjoraker

Auto-generated profile, based on publicly available information

Kendra J. Bjoraker

3:1 Neuropsychology Consultants, PLLC, Minneapolis, MN, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in The Journal of Pediatrics
Verified
Journal Article
Open access
KBKendra J. Bjoraker
Kendra J. Bjoraker
MSMichael A. Swanson
Michael A. Swanson
Curtis CoughlinCurtis Coughlin
Curtis Coughlin
JCJohn Christodoulou
John Christodoulou
ETEe S. Tan
Ee S. Tan
JHJohan L.K. Van Hove
Johan L.K. Van Hove
To evaluate the impact of sodium benzoate and dextromethorphan treatment on patients with the attenuated form of nonketotic hyperglycinemia. Families were recruited with 2 siblings both affected with attenuated nonketotic hyperglycinemia. Genetic mutations were expressed to identify residual activity. The outcome on developmental progress and seizures was compared between the first child diagnosed and treated late with the second child diagnosed at birth and treated aggressively from the newborn period using dextromethorphan and benzoate at dosing sufficient to normalize plasma glycine levels. Both siblings were evaluated with similar standardized neurodevelopmental measures. In each sibling set, the second sibling treated from the neonatal period achieved earlier and more developmental milestones, and had a higher developmental quotient. In 3 of the 4 sibling pairs, the younger sibling had no seizures whereas the first child had a seizure disorder. The adaptive behavior subdomains of socialization and daily living skills improved more than motor skills and communication. Early treatment with dextromethorphan and sodium benzoate sufficient to normalize plasma glycine levels is effective at improving outcome if used in children with attenuated disease with mutations providing residual activity and when started from the neonatal period.

28 July 2022 in Molecular Genetics and Metabolism
Verified
Journal Article
Open access
Barbara K. BurtonBarbara K. Burton
Barbara K. Burton
Alvaro HermidaAlvaro Hermida
Alvaro Hermida
ABAmaya Bélanger-Quintana
Amaya Bélanger-Quintana
HBHeather Bell
Heather Bell
KBKendra J. Bjoraker
Kendra J. Bjoraker
AMAnia C. Muntau
Ania C. Muntau
Early treated patients with phenylketonuria (PKU) often become lost to follow-up from adolescence onwards due to the historical focus of PKU care on the pediatric population and lack of programs facilitating the transition to adulthood. As a result, evidence on the management of adolescents and young adults with PKU is limited. Two meetings were held with a multidisciplinary international panel of 25 experts in PKU and comorbidities frequently experienced by patients with PKU. Based on the outcomes of the first meeting, a set of statements were developed. During the second meeting, these statements were voted on for consensus generation (≥70% agreement), using a modified Delphi approach. A total of 37 consensus recommendations were developed across five areas that were deemed important in the management of adolescents and young adults with PKU: (1) general physical health, (2) mental health and neurocognitive functioning, (3) blood Phe target range, (4) PKU-specific challenges, and (5) transition to adult care. The consensus recommendations reflect the personal opinions and experiences from the participating experts supported with evidence when available. Overall, clinicians managing adolescents and young adults with PKU should be aware of the wide variety of PKU-associated comorbidities, initiating screening at an early age. In addition, management of adolescents/young adults should be a joint effort between the patient, clinical center, and parents/caregivers supporting adolescents with gradually gaining independent control of their disease during the transition to adulthood. A multidisciplinary international group of experts used a modified Delphi approach to develop a set of consensus recommendations with the aim of providing guidance and offering tools to clinics to aid with supporting adolescents and young adults with PKU.

1 June 2021 in Molecular Genetics and Metabolism Reports
Verified
Journal Article
Open access
DODaniele Suzete Persike de Oliveira
Daniele Suzete Persike de Oliveira
KBKendra J. Bjoraker
Kendra J. Bjoraker